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Abstract
Hypoxia inducible factor 1a (Hif1a) is a stress responsive transcription factor, which regulates the expression of genes
required for adaption to hypoxia. Hif1a is normally hydroxylated by an oxygen-dependent prolylhydroxylase, leading to
degradation and clearance of Hif1a from the cell. Under hypoxic conditions, the activity of the prolylhydroxylase is reduced
and Hif1a accumulates. Hif1a is also constitutively expressed in tumor cells, where it is associated with resistance to ionizing
radiation. Activation of the Hif1a transcriptional regulatory pathway may therefore function to protect normal cells from
DNA damage caused by ionizing radiation. Here, we utilized the prolylhydroxylase inhibitor dimethyloxalylglycine (DMOG)
to elevate Hif1a levels in mouse embryonic fibroblasts (MEFs) to determine if DMOG could function as a radioprotector. The
results demonstrate that DMOG increased Hif1a protein levels and decreased the sensitivity of MEFs to ionizing radiation.
Further, the ability of DMOG to function as a radioprotector required Hif1a, indicating a key role for Hif1a’s transcriptional
activity. DMOG also induced the Hif1a -dependent accumulation of several DNA damage response proteins, including CHD4
and MTA3 (sub-units of the NuRD deacetylase complex) and the Suv39h1 histone H3 methyltransferase. Depletion of
Suv39h1, but not CHD4 or MTA3, reduced the ability of DMOG to protect cells from radiation damage, implicating increased
histone H3 methylation in the radioprotection of cells. Finally, treatment of mice with DMOG prior to total body irradiation
resulted in significant radioprotection of the mice, demonstrating the utility of DMOG and related prolylhydroxylase
inhibitors to protect whole organisms from ionizing radiation. Activation of Hif1a through prolylhydroxylase inhibition
therefore identifies a new pathway for the development of novel radiation protectors.
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Introduction
Hypoxia is associated with inflammatory diseases, tumors and
wound healing [1]. Hypoxia increases the levels of the hypoxia
inducible factor (HIF), a transcription factor that alters gene
expression and promotes adaptation of cells to hypoxic environ-
ments. HIF is a heterodimeric transcription factor composed of the
hypoxia inducible Hif1a subunit and the constitutively expressed
Hif1b [2]. Under normal oxygen tension, Hif1a is hydroxylated by
the HIF-prolylhydroxylase PHD2, facilitating interaction with the
VHL E3 ubiquitin ligase complex [3,4]. Hif1a is then targeted for
ubiquitin-dependent degradation [5], and Hif1a protein levels
remain low. Because HIF-prolylhydroxylases require oxygen to
hydroxylate Hif1a [5], hypoxia inhibits PHD2 hydroxylase
activity, decreasing hydroxylation of Hif1a, and allowing Hif1a
to accumulate. Hif1a then forms an active transcriptional complex
with Hif1b, and upregulates expression of more than 60 genes
which are required for cells to survive under low oxygen tension,
including angiogenic factors, erythropoietin, glycolytic enzymes
and survival factors [6]. Activation of Hif1a therefore regulates
multiple biological pathways which promote cell survival under
conditions of stress [5,7,8].
Hif1a also plays a key role in both tumor growth and sensitivity
of tumors to chemotherapy and radiotherapy. Many tumors
express high levels of constitutive Hif1a which is associated with
resistance to therapy and poor prognosis [9–12]. Reducing Hif1a
expression using either genetic or pharmacological approaches
both decreases tumor growth and sensitizes tumors to radiation
therapy and to chemotherapy [13–16]. Further, cells in which
Hif1a is inactivated, including both Hif1a
2/2 MEFs [9] and
tumor cell lines, exhibit increased sensitivity to both chemotherapy
and radiotherapy [9,14,17,18]. These observations clearly indicate
that cells expressing high levels of Hif1a are more resistant to
DNA damaging agents, presumably due to the transcriptional
activation of pro-survival genes by Hif1a. Hif1a levels may also be
increased by exposure to ionizing radiation [18,19]. Although the
contribution of Hif1a to mediating resistance to radiation therapy
varies between cell and tissue types [16,20], it is now clear that
increased Hif1a levels can have profound impacts on the
sensitivity of both normal and tumor cells to cancer therapy.
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ylase which hydroxylates Hif1a and promotes its degradation [21].
These prolylhydroxylase inhibitors can be employed to stabilize
Hif1a in cells so that the contribution of Hif1a to specific cellular
pathways can be assessed. Prolyl hydroxylases (PH) are members
of an extended family of Fe (II) and 2-oxoglutarate dependent
dioxygenases [22], which function to hydroxylate proteins on
multiple amino-acids, including proline [22,23]. Small molecule
inhibitors of prolylhydroxylases include compounds which are
structural analogs to the 2-oxoglutarate co-factor required for
these enzymes to function [22]. One of these, dimethyloxalylgly-
cine (DMOG), is a cell-permeable inhibitor of both proline and
asparaginyl hydroxylases [24], which can activate the Hif1a
dependent gene expression both in vitro [25] and in vivo [26].
Prolylhydroxylase inhibitors such as DMOG have been shown to
promote cell survival under conditions of hypoxia or growth factor
deprivation by elevating levels of Hif1a [25,27–29]. Elevating
levels of Hif1a through inhibition of prolylhydroxylase function is
therefore an effective method for modulating Hif1a function.
Currently, there is significant interest in the development of
radioprotective agents which can be used to protect against
exposure to ionizing radiation. This can include protection of
normal tissue from radiation injury during radiation therapy of
tumors, as well as developing medical countermeasures to protect
large populations against accidental exposure to radiation.
Elevated levels of Hif1a are strongly associated with radio-
resistance [9–12], indicating that increasing Hif1a levels in normal
tissues may function to protect them from radiation damage. Here,
we demonstrate that activation of the Hif1a pathway by the
prolylhydroxylase inhibitor DMOG can protect normal cells from
exposure to radiation.
Results
To examine if activation of Hif1a impacted radiosensitivity, we
first examined if exposure of MCF-7 cells to ionizing radiation (IR)
lead to stabilization of the Hif1a transcription factor. MCF-7 cells
were exposed to IR or treated with the prolylhydroxylase
inhibitors DMOG [26] or CoCl2 [27]. Both DMOG and CoCl2
caused significant accumulation of Hif1a in MCF-7 cells
(figure 1A), as previously reported [26,27]. Exposure to IR alone
had only a slight impact on accumulation of Hif1a, indicating that
IR does not cause significant stabilization of Hif1a. However,
combining IR with either DMOG or CoCl2 led to much larger
accumulation of Hif1a protein than exposure to DMOG or CoCl2
alone (figure 1B). This indicates that DMOG and IR function
synergistically to stabilize Hif1a and increase the accumulation of
this protein in cells.
Previous work indicated that upregulation of Hif1a by
treatment with the prolylhydroxylase inhibitor DMOG can
improve survival under conditions of stress [25,27–29]. Because
DMOG functioned synergistically with IR to promote accumula-
tion of Hif1a (figure 1B), we determined if the increased levels of
Hif1a caused by DMOG affected radiosensitivity. For these
experiments, MEFs were used. These were chosen because MEFs,
unlike tumor derived or transformed cells, do not express basal
levels of Hif1a which can impact intrinsic radiosensitivity [13–16].
This allows for the direct assessment of the impact of increased
Hif1a expression on radiosensitivity. When MEFs were treated for
24 hr with DMOG to increase Hif1a levels, there was a significant
decrease in radiosensitivity (figure 1C), indicating that DMOG
functions as a radioprotector. Figure 1 therefore indicates that
upregulation of Hif1a can protect MEFs from the cytotoxic effects
of IR.
Hif1a functions as a transcriptional regulator [30], suggesting
that Hif1a may control the transcription of DNA repair proteins
(or apoptotic factors), which can protect cells from radiation
damage. Recent work has implicated components of the NuRD
deacetylase complex in the cells response to both hypoxia [31] and
DSB repair [32,33]. The NuRD complex, which contains both
the CHD4 ATPase and the HDAC2 deacetylase, is required for
cells to repair and survive IR-induced DNA damage [32,33].
Importantly, expression of the MTA1 sub-unit of NuRD is
induced under hypoxic conditions [31,34], and both MTA1 and
histone deacetylases contribute to Hif1a stability [34]. This
indicates that components of the NuRD complex may be
upregulated by Hif1a. Therefore, we examined if components of
the NuRD complex were increased by hypoxia mimics and if this
induction contributed to the observed radioprotection by DMOG.
Figure 1. Upregulation of Hif1a promotes radioprotection. (A)
MCF-7 cells were incubated in DMOG (1 mM) or CoCl2 (200 mM) for
10 hr or exposed to 10Gy of ionizing radiation (IR) for the indicated
times. Cell extracts were prepared and examined by western blot (WB)
analysis to monitor levels of Hif1a. b-actin levels are shown to
demonstrate equal loading. (B) MCF-7 cells were incubated in DMOG
(1 mM) or CoCl2 (200 mM) for the indicated times. Cells were irradiated
(10Gy) at time zero where indicated. Cell extracts were prepared and
examined by western blot (WB) analysis to monitor levels of Hif1a. b-
actin levels are shown to demonstrate equal loading. (C) MEFs were
preincubated in DMOG (1 mM) for 1 hr, followed by exposure to IR as
indicated. 24 hours later, DMOG was removed and clonogenic cell
survival assays carried out.N=DMOG, #=solvent (PBS).
doi:10.1371/journal.pone.0026064.g001
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reduced expression of Hif1a using shRNA. shRNA targeting
Hif1a blocked the accumulation of Hif1a after treatment with
either DMOG or CoCl2 (figure 2A) and reduced the levels of
Hif1a mRNA (figure 2B). Silencing of Hif1a also inhibited
the accumulation of VEGF mRNA (figure 2C), a key target of
Hif1a [30], demonstrating that Hif1a function is abolished in the
shRNA
Hif1a cells. Next, we determined if Hif1a regulates
expression of the CHD4 and MTA3 genes. Figure 2D and 2E
demonstrate that activation of Hif1a by CoCl2 increased the levels
of CHD4 and MTA3 mRNA, and this increase was abolished
when Hif1a was silenced with shRNA (figure 2D and 2E). This
demonstrates that Hif1a is required for the accumulation of
CHD4 and MTA3 mRNA after exposure to CoCl2. Further,
CoCl2 increased the levels of Hif1a, CHD4 and MTA3 protein
with similar kinetics (figure 2F), consistent with the Hif1a-
dependent increase in their mRNA levels (figure 2D and 2E).
Significantly, suppression of Hif1a with shRNA also reduced the
basal levels of CHD4 protein, whereas basal levels of MTA3 were
unaffected by loss of Hif1a (figure 2E, 2F). Further, loss of Hif1a
greatly attenuated the accumulation of CHD4 after exposure to
CoCl2, but had only a small impact on the accumulation of MTA3
protein (figure 2F). Figure 2 therefore demonstrates that increased
levels of Hif1a lead to increased levels of MTA3 and CHD4
mRNA, potentially identifying CHD4 and MTA3 as transcrip-
tional targets for Hif1a. Significantly, loss of Hif1a decreased both
the basal and stimulated levels of CHD4 protein, indicating
that Hif1a plays a critical role in maintaining basal and stimu-
lated levels of CHD4. Previous work indicates that CHD4 can
participate in the cells response to IR-induced DNA damage
[32,33]. This suggests that, because cells expressing shRNA to
Hif1a have decreased levels of CHD4, they should be more
sensitive to IR. Figure 3A demonstrates that cells lacking Hif1a
exhibit a small but significant increase in radiosensitivity,
consistent with a key role for Hif1a in regulating radiosensitivity.
However, when shRNA was used to deplete CHD4 protein levels
to a level similar to those detected in Hif1a depleted cells (compare
figure 2F and 3B, inset) no significant impact on radiosensitivity
was seen (figure 3B). Similarly, silencing MTA3 expression with
shRNA did not alter cellular radiosensitivity (data not shown). We
interpret this to mean that, while Hif1a contributes to cell survival
after exposure to IR (figure 1C and figure 3A), this regulation of
radiosensitivity is not mediated through the ability of Hif1a to
regulate the expression of either CHD4 or MTA3. Therefore,
although we have identified CHD4 and MTA3 as potential
transcriptional targets for Hif1a, the ability of Hif1a to protect
cells from radiation damage does not require either CHD4 or
MTA3. It is more likely that upregulating CHD4 and MTA3,
which are components of NuRD deacetylase complex, plays a key
role in other processes, such as transcriptional repression, which
are a feature of the hypoxia response [4,6,30].
To further explore how stabilization of Hif1a regulates
radiosensitivity, we examined a second group of proteins, the
histone demethylases, which are transcriptionally activated by
Hif1a. Histone methylation is a dynamic signal transduction
process, controlled by histone methyltransferases [35,36] and
histone demethylases (KDMs) [37,38]. Histone methylation plays
a key role in regulating chromatin structure, transcriptional
activity and the DNA damage response [39,40]. The importance
of histone methylation in the DNA damage response is highlighted
by the observation that inactivation of H3K9me3 methyltransfer-
ases leads to genomic instability and an inability to correctly repair
DSBs caused by IR [41,42]. Several KDMs [43], including
KDM4B and KDM3A [44], contain Hypoxia Response Elements
(HRE) and are transcriptionally activated by Hif1a under hypoxic
conditions [43,44], suggesting that histone methylation may
decrease under hypoxic conditions. Accordingly, we examined
how the stabilization of Hif1a by DMOG impacts methylation of
H3K9me3. In figure 4A, exposure of cells to DMOG rapidly
increased H3K9me3 in cells. This was somewhat unexpected,
since Hif1a transcriptionally upregulates 2 H3K9me3 specific
KDMs, KDM4B and KDM3A [43,44], and should therefore
Figure 2. Hif1a increases transcription of the CHD4 and MTA3
genes. (A) MCF-7 cells stably expressing either a non-specific shRNA
(shRNA
Con) or shRNA targeting Hif1a (shRNA
Hif1a) were exposed to
DMOG (1 mM) or CoCl2 (200 mM) for 24 hrs. Cell extracts were prepared
and then examined by western blot (WB) analysis to monitor levels of
Hif1a. b-actin levels are shown to demonstrate equal loading. (B–E)
MCF-7 cells stably expressing either a non-specific shRNA (shRNA
Con)o r
shRNA targeting Hif1a (shRNA
Hif1a) were exposed to solvent (open bars)
or CoCl2 (200 mM; filled bars) for 8 hr. mRNA levels for the indicated
genes were measured by RT-PCR as described in methods. Results 6 SE
(n=3). (F) MCF7 cells stably expressing either a non-specific shRNA
(shRNA
Con) or shRNA targeting Hif1a (shRNA
Hif1a) were exposed to
CoCl2 (200 mM) for indicated number of hours. Cell extracts were
prepared and then examined by western blot (WB) analysis to monitor
levels of CHD4, MTA3 and Hif1a. b-actin levels are shown to
demonstrate equal loading.
doi:10.1371/journal.pone.0026064.g002
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prolylhydroxylases belong to the larger family of dioxygenases
[22]. Both the Hif1a prolylhydroxylases and KDMs utilize an Fe
(II) and 2-oxoglutarate-dependent dioxygenase mechanism to
either hydroxylate proline on Hif1a [4] or remove methyl groups
from methylated lysines on histone tails [37,38]. DMOG, which is
a 2-oxoglutarate analog, is a competitive inhibitor of the Hif1a-
PH and is therefore likely to inhibit KDMs as well. In figure 4B,
the H3K9me3 specific demethylase KDM4A was transiently
expressed in cells. Cells expressing vector showed increased
H3K9me3 methylation when cells were exposed to DMOG,
consistent with inhibition of endogenous KDMs. Overexpression
of KDM4A resulted in almost complete loss of endogenous
H3K9me3 in the cells; however, addition of DMOG to cells
expressing KDM4A restored H3K9me3 levels to near normal.
Figure 4B therefore clearly demonstrates that DMOG, in addition
to increasing Hif1a protein levels, can also inhibit endogenous
KDMs and therefore increase levels of H3K9me3 in the cells.
To further analyze how DMOG may regulate H3K9me3 levels,
we also determined if Hif1a could increase expression of Suv39h1,
a key H3K9me3 methyltransferase [42]. Surprisingly, figure 4C
and 4D demonstrate that both DMOG and, to a lesser extent,
CoCl2, increased expression of the Suv39h1 methyltransferase.
Further, the increase in Suv39h1 protein closely followed the dose-
dependent (figure 4C) and time-dependent (figure 4D) increase in
Hif1a levels caused by DMOG. Importantly, both basal and
DMOG dependent induction of Suv39h1 were abolished in cells
lacking Hif1a (figure 4E), indicating that Hif1a directly regulates
the levels of Suv39h1 in cells. Figure 4 therefore demonstrates that
DMOG can influence H3K9me3 levels by directly inactivating
H3K9 demethylases (figure 4A and 4B) as well as upregulating
H3K9 methyltransferases through a Hif1a dependent mechanism
Figure 4C–E).
The previous results indicate that DMOG may influence
radiosensitivity through 2 distinct pathways. First, DMOG can
directly inhibit KDMs, increasing H3K9me3 levels by a
mechanism which is independent of Hif1a. Second, DMOG can
directly inhibit Hif1a-prolylhydroxylases, leading to stabilization
and accumulation of transcriptionally active Hif1a. To determine
the relative contributions of these 2 pathways to the ability of
DMOG to function as a radioprotector, we examined how
silencing of Hif1a with shRNA impacted radioprotection.
Figure 5A demonstrates that DMOG increased radioresistance
in MEFs expressing a non-specific shRNA, but this effect was lost
when Hif1a was silenced. The ability of DMOG to function as a
radioprotector therefore requires Hif1a, indicating that DMOG
exerts its primary effect on radiosensitivity through inhibition of
the Hif1a-prolylhydroxylase and accumulation of Hif1a. There-
fore, although DMOG can also inhibit KDMs (figure 4A and 4B),
this inhibition does not appear to be critical for the observed
radioprotection.
Finally, we examined if the Hif1a -dependent increase in
expression of the Suv39h1 methyltransferase was required for
DMOG dependent radioprotection. For this, we determined if
DMOG can protect MEFs lacking both the Suv39h1 and Suv39h2
methyltransferases (Suv
DKO cells; [42]). The ability of DMOG and
CoCl2 to increase Hif1a levels was not altered in the Suv
DKO
MEFs (figure 5B). Further, whereas DMOG functioned as a
radioprotector in normal MEFs (figure 5A), the protective effect of
DMOG was significantly reduced in the Suv
DKO MEFs (figure 5C).
This indicates that the reduced ability of DMOG to protect
Suv
DKO MEFs may be attributed to both the loss of Hif1a
dependent increase in the Suv39h1 methyltransferase, as well as
changes in other Hif1a target genes. Overall, figure 5 demon-
strates that DMOG can protect cells form radiation by stabilizing
the Hif1a transcription factor, and increasing expression of genes,
including the Suv39h1 methyltransferase, which can promote cell
survival.
Finally, we sought to determine if DMOG could protect cells
from DNA damage at the level of the whole organism. Hif1a
activation can transcriptionally activate a wide range of genes,
including VEGF, which promote angiogenesis, and erythropoietin,
which mobilizes bone marrow and improves blood parameters
[29,45]. It is likely that these factors may be important in
promoting recovery of sensitive tissues, such as the bone marrow
and gastrointestinal tract, from total body irradiation [46]. In
order to assess if the radioprotective effects of DMOG can be
detected at the level of the whole organism, we examined if
DMOG had protective effects in a murine total body irradiation
(TBI) model. DMOG was injected ip into either C57BL/6J
Figure 3. Radiosensitivity of cells lacking Hif1a or CHD4. (A)
MCF-7 cells stably transfected with control (shCon) or Hif1a (sh
Hif1a)
shRNA or (B) HEK293T cells stably transfected with control (shCon) or
CHD4 (shCHD4) shRNA were irradiated as indicated and clonogenic cell
survival assays carried out. Western blot analysis of CHD4 protein levels
shown in figure 3B (inset). Results 6 SE (n=3).
doi:10.1371/journal.pone.0026064.g003
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TBI model systems. DMOG alone did not cause any toxicity, with
100% of the mice surviving at 30 days (data not shown), in
agreement with previous studies using DMOG [47]. TBI at 8Gy
caused 80% and 100% lethality in saline-treated C57BL/6J and
Balb/c mice respectively (figure 6A and 6B). However, DMOG
treatment significantly improved the survival of both C57BL/6J
and Balb/c mice and rescued them from radiation induced
lethality. Activation of Hif1a by DMOG results in the transcrip-
tional upregulation of many genes and growth factors and is
associated with increased cell survival in culture and protection of
mice from whole body irradiation. These results clearly demon-
strated that DMOG exhibits radioprotective potential in murine
models.
Discussion
The Hif1a transcriptional regulatory protein controls the
expression of genes which promote cell survival under conditions
of low oxygen tension [2]. Hif1a can switch cell metabolism
towards increased expression of growth factors and anti-apoptotic
factors as well as switching of metabolic pathways, allow the cell to
maintain energy levels under hypoxic conditions [2,4,6]. Hif1a
levels are controlled through direct hydroxylation of Hif1a by the
PHD2 prolylhydroxylase, leading to degradation of Hif1a under
normal oxygen tension [3–5]. Small molecule inhibitors of
prolylhydroxylases have been developed which inhibit PHD2
and related enzymes, leading to stabilization of Hif1a and
upregulation of the hypoxia response [8,25,48]. Here, we have
shown that stabilization of Hif1a using the prolylhydroxylase
inhibitor DMOG protects both MEFs and mice from the cytotoxic
effects of exposure to IR. This is consistent with previous studies
demonstrating that tumor cells containing constitutively high levels
of Hif1a are more resistant to both chemotherapy and
radiotherapy [9–16]. Increasing Hif1a levels in normal cells with
prolylhydroxylase inhibitors such as DMOG therefore represents a
novel pathway for the development of new and effective
radioprotective agents.
Our results clearly show that DMOG requires Hif1a to protect
cells from radiation, since suppression of Hif1a with shRNA
abolished the protective effect of DMOG. A key question is to
determine how stabilization of Hif1a by DMOG can promote
radioprotection. Because Hif1a functions as a transcriptional
activator, it likely exerts its protective effects through increased
expression of genes involved in DNA repair or cell survival.
Previous studies indicate that hypoxia can alter expression of
components of the mismatch repair pathway [49,50]; however,
altered expression of these proteins would not account for
radioprotection observed after activation of Hif1a by DMOG.
However, we identified 3 new targets for Hif1a - the CHD4
helicase, the MTA3 regulatory protein and the Suv39h1
methyltransferase. All 3 were increased at both the mRNA and
protein level by DMOG and the hypoxia mimetic agent CoCl2.
Figure 4. DMOG inhibits lysine demethylases and increases levels of the Suv39h1 methyltransferase. (A) MEFs were incubated in either
solvent (Control: DMSO) or DMOG (1 mM) for 24 hr. H3K9me3 levels were detected by immunofluorescent staining with antibody to H3K9me3 and
co-stained with DAPI to locate nuclear DNA. (B) HEK293T cells were transiently transfected with vector or KDM4A and allowed to recover for 30 hrs.
Cells were either untreated or incubated with DMOG (1 mM) for 24 hrs. H3K9me3 levels were detected by immunofluorescent staining with antibody
to H3K9me3. (C) MCF-7 cells were incubated in increasing concentrations of DMOG or CoCl2 (200 mM) for 24 hrs. Cell extracts were prepared and
examined by western blot (WB) analysis to monitor levels of Hif1a and Suv39h1. b-actin levels are shown to demonstrate equal loading. (D) MCF-7
cells were incubated in DMOG (1 mM) or CoCl2 (200 mM) for the indicated time. Cell extracts were prepared and examined by western blot (WB)
analysis to monitor levels of Hif1a and Suv39h1. b-actin levels are shown to demonstrate equal loading. (E) MCF-7 cells expressing either a non-
specific shRNA (shRNA
Con) or shRNA targeting Hif1a (shRNA
Hif1a) were incubated with DMOG or CoCl2 (200 mM) for 24 hrs. Cell extracts were
prepared and examined by western blot (WB) analysis to monitor levels of Hif1a and Suv39h1. b-actin levels are shown to demonstrate equal loading.
doi:10.1371/journal.pone.0026064.g004
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factor, suggesting that Hif1a can directly regulate their transcrip-
tion. Previous work has shown that MTA1, a close family member
related to MTA3, is also transcriptionally upregulated by Hif1a
during hypoxia [31], implying that the MTA family of coactivators
are a common target for the Hif1a transcription factor. Both
CHD4 and MTA3 are components of the NuRD complex, a
histone deacetylase complex which is implicated in DNA repair
[32,33]. Inactivation of CHD4 leads to increased sensitivity to IR-
induced DNA damage [32,33], indicating a key role in the repair
of DSBs. Taken together, this would suggest that increased levels
of NuRD may protect cells from radiation. However, although
Hif1a was important for DMOG to protect cells from IR, loss of
either CHD4 or MTA3 expression did not alter sensitivity to IR in
our cell system. We interpret this to mean that, although DMOG
can stabilize Hif1a and increase levels of the NuRD complex, the
accumulation of NuRD does not significantly impact the
radiosensitivity of the cells. The accumulation of the NuRD
deacetylase complex may therefore play an alternate role in the
hypoxia response, such as transcriptional repression of genes
during low oxygen tension.
An alternate explanation for how DMOG may protect cells
from radiation damage can be proposed based on the previous
observation that Hif1a can alter expression of genes involved in
the regulation of histone methylation. Hif1a increases expression
of histone demethylases, including KDM4A and KDM4B [43,44],
which function to remove methyl groups from methylated histones
on the chromatin. The increased expression of KDMs during
hypoxia is associated with a decrease in histone methylation,
including a reduction on H3K9me3 levels [43,44]. Previous work
Figure 5. DMOG protects cells from radiation by stabilizing the
Hif1a protein. (A) MEFs expressing a non-specific shRNA (#,N;s h
Con)
or shRNA targeting Hif1a (%, &;s h
Hif1a) were untreated (#, %)o r
preincubated for 1 hr in DMOG (N, &; 1 mM), irradiated at the indicated
dose and allowed to recover for 24 hr. DMOG was removed by medium
exchange and clonogenic cell survival assays carried out following 10–12
days growth in culture. Results 6 SE (n=6). (B) Wild type MEFs or MEFs
derived from mice with a double knockout of Suv39h1 and Suv39h2
(MEF-Suv
DKO) were incubated with DMOG (1 mM) or CoCl2 (200 mM) for
24 hrs. Cell extracts were prepared and examined by western blot (WB)
analysis to monitor levels of Hif1a. b-actin levels are shown to
demonstrate equal loading. (C) MEFs derived from mice with a double
knockout of Suv39h1 and Suv39h2 (MEF-Suv
DKO) were incubated with
solvent (#)o rD M O G(N; 1 mM) for 1 hr, irradiated at the indicated dose
and allowed to recover for 24 hrs. DMOG was removed by medium
exchange, cells allowed to recover for 10–12 days, and clonogenic cell
survival assays carried out. Results 6 SE (n=3).
doi:10.1371/journal.pone.0026064.g005
Figure 6. DMOG improves survival of mice following total body
irradiation. Mice were irradiated (8Gy TBI) and survival monitored over
30 days. DMOG (100 mg/kg) or saline was administered ip 4 hrs before
TBI, and 12 hrs and 36 hrs after TBI. Kaplan-Meier survival plots of (A)
C57BL/6J (**p=0.037) and (B) Balb/c mice (**p=0.019) are shown.
doi:10.1371/journal.pone.0026064.g006
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increase in radiosensitivity [41]. Hif1a -dependent increases in
KDM expression would therefore be predicted to increase, rather
than decrease, radiosensitivity. However, we found that, unlike
hypoxia [43,44], DMOG increased rather than decreased
H3K9me3 levels. This result is explained by the fact that KDMs
and Hif1a-prolylhydroxylases share a common catalytic mecha-
nism [22], so that both classes of enzyme are inhibited by DMOG
(figure 4B). DMOG therefore inhibits the Hif1a-prolylhydrox-
ylase, leading to accumulation of transcriptionally active Hif1a
and upregulation of KDMs [43,44]. However, because DMOG
can also directly inhibit KDMs (figure 4b), this essentially negates
the increased expression of KDMs mediated by Hif1a. Overall,
DMOG will increase histone methylation through inhibition of
KDMs. Further, cells in which Hif1a was inactivated were not
protected by DMOG, despite the ability of DMOG to increase
H3K9me3 levels in these cells. We conclude that the ability of
DMOG to protect cells from IR is mediated through the
transcriptional activity of Hif1a rather than through a general
inhibition of endogenous KDMs in the cell.
In addition to CHD4 and MTA3, we also identified the
Suv39h1 methyltransferase as a target of the Hif1a. Suv39h1 is a
key player in the di- and trimethylation of H3 on lysine 9 [42].
Further, loss of Suv39h1 and decreased levels of H3K9me3 are
associated with increased radiosensitivity [41] and decreased
genomic stability [42]. Secondly, DMOG can also increase the
expression of Suv39h1 through activation of Hif1a, a process
which will also tend to increase H3K9me3 levels. Importantly, the
ability of DMOG to function as a radioprotector was significantly
reduced (but not abolished) in MEFs which lacked expression
of Suv39h1 and Suv39h2. Since DMOG increases Suv39h1
expression through a Hif1a dependent mechanism, this indicates
that the main contributor to DMOG mediated radioresistance is
the transcriptional upregulation of the Suv39h1 methyltransferase
by Hif1a. How can increased expression of Suv39h1 impact
radiosensitivity? As discussed above, cells lacking Suv39h1 have
significant defects in both H3K9me3 and in DSB repair [41,42].
DMOG may therefore increase expression of Suv39h1, leading to
increased methylation of H3K9 and allowing for more efficient
activation of the DNA damage response. Suv39h1 may therefore
methylate H3K9 within specific regions of the chromatin after
DNA damage in order to improve the efficiency of repair.
However, it is also possible that the radioprotective effects of
increased Suv39h1 are not directly on the DNA repair machinery,
but instead feedback through altered methylation of key genes,
such as anti-apoptotic proteins. Overall, the protective effect of
DMOG is largely mediated through the Hif1a dependent increase
in expression of the Suv39h1 methyltransferase, leading to
increased H3K9me3 levels in the cell.
Finally, we also demonstrated that when DMOG was given to
mice prior to irradiation it can protect them from total body
irradiation. Significant improvement in survival was found in 2
different mouse strains, underlining the effectiveness of DMOG in
a whole animal model. Previous studies using DMOG and related
prolylhydroxylase inhibitors in whole animal models have
indicated protection from ischemic injury [51], protection in a
murine model of colitis [47] and the development of hypoxia
tolerance [29]. A key target of Hif1a are the growth factors VEGF
and erythropoietin [2]. DMOG can detectably increase erythro-
poietin levels in animal models [29,45], leading to improvement in
blood parameters, and can act to increase angiogenesis and muscle
recovery from ischemic injury [26]. The most sensitive tissues to
IR are the GI tract and bone marrow [46]. The ability of DMOG
to stimulate the production of factors such as erythropoietin and
VEGF, which can stimulate repopulation of the hematopoietic
progenitors and promote formation of new vasculature, are likely
to be critical factors in the ability of DMOG to protect whole
animals from radiation.
Effective radioprotectors and radiation-mitigating agents are
needed in the clinic to treat the radiation victims and to protect
individuals from radiation exposure resulting from nuclear
disasters or radiological attack. Many small molecules, including
anti-oxidants, cytokines, activators of NF-KappaB and cyclin-
dependent kinase inhibitors have been shown to have radiopro-
tective effects in murine TBI models [52–57]. Our studies
demonstrate that the prolyl hydroxylase inhibitor DMOG is an
effective radioprotector in both tissue culture and whole animal
models. Activation of Hif1a evokes a complex response at both the
cellular and whole organism levels. Changes in gene transcription
caused by DMOG at the cellular level, including changes in
histone methylation, can impact the ability of individual cells to
repair and survive radiation exposure. In addition, the ability of
DMOG to stabilize Hif1a and stimulate production of growth
factors such as VEGF and erythropoietin can promote DNA
repair, the repopulation of sensitive cell types and promote
survival at both the level of individual tissues and the whole
organism. Manipulation of the Hif1a transcriptional pathway may
reveal new targets for the development of novel radioprotective
agents.
Materials and Methods
Cell Culture
HEK293T, MCF-7 (ATCC, NJ) and MEF [42] cells were
cultured as previously described [42,58]. Cells were irradiated
using a Cs
137 irradiator and clonogenic cell survival monitored as
in [58]. Dimethyloxalylglycine was purchased from Frontier
Scientific (Logan, UT). HEK293T, MCF7, and MEF cells were
transfected using Lipofectamine 2000 according to the manufac-
turer’s instructions (Invitrogen, CA), and selected using puromy-
cin. Lentiviral Hif1a shRNA and GFP control shRNA were
obtained from The RNAi Consortium (Broad Institute, Cam-
bridge, MA). Plasmids were packaged with VSV-G expressing
constructs phCMV-G and PCMVd8.2 plasmid and transfected
into HEK293T cells using Lipofectamine 2000. After 48 h, viral
particles were harvested from the culture medium and used to
prepare stable cell lines expressing GFP or Hif1a shRNA after
selection with puromycin. The histone demethylase KDM4A was
transiently expressed in HEK293T cells using Fugene-6 (Roche,
IN) for 30 hr prior to use for experimental protocols.
Cell lysates and Western blot analysis
Antibodies used: m Hif1a (Santa Cruz Biotechnology, CA);
hHIF1a (Abcam, CA); H3K9me3 (Millipore, NY); b-actin (Cell
Signaling Technology, MA); CHD4 and MTA3 (Bethyl Labora-
tories, TX); Suv39h1 (Novus, CA). To prepare nuclear lysates,
cells were resuspended in 500 ml buffer A (10 mM Tris, pH8.0;
1 mM EDTA, pH8.0; 150 mM NaCl; 0.5% NP-40; 1 mM PMSF;
5 mg/ml leupeptin; 20 mg/ml aprotinin), incubated on ice for
15 min and centrifuged at 500 g for 5 min at 4uC. Supernatant
was removed and the pellet resuspended in buffer B (20 mM
Hepes, pH7.9; 400 mM NaCl; 1 mM EDTA; 0.5 mM DTT;
1 mM PMSF; 5 mg/ml leupeptin; 20 mg/ml aprotinin), incubated
on ice for 15 min and cleared by centrifugation (21,000 g for
5 min at 4uC). For western blots, equal amounts of protein
(Bradford Protein Assay kit, Bio-Rad Laboratories, CA) were
separated by electrophoresis and transferred to nitrocellulose
membranes (Bio-Rad Laboratories, CA). Membranes were
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with primary antibodies for 3 h, and washed in PBST (PBS and
0.1% Tween-20) followed by goat anti–mouse IR Dye-800CW or
goat anti-rabbit IR Dye-680CW secondary antibodies (Li-Cor,
NB). Imaging was performed using the Li-Cor Odyssey Near Infra
Red System, and analyzed using the Odyssey software system 3.0
package (Li-Cor, NB).
RT-PCR
Total RNA was prepared using RNeasy kit (Qiagen, CA). 1 mg
RNA and supplied random primers were used to generate cDNA
with aid of QuantiTect reverse transcription kit (Qiagen, CA). RT-
qPCR was performed using following primers: for Hif1a 59-
AACATAAAGTCTGCAACATGGAAG and 59-TTTGAT-
GGGTGAGGAATGGG; for CHD4 59-CAGAGCTATTG-
GAATCACAGGG and 59-TCGCTCATACTTCACTGTTGG;
for MTA3 59-GAGGCTGACTTGACCGATAAG and 59-
TGTCTCATTCAGAAGGGCAAC; VEGF primers were used
as positive control and 18S RNA primers were used as internal
control.
Immunofluorescence
Cells (on cover slides) were fixed in phosphate-buffered saline
(PBS) containing 2% paraformaldehyde. Cells were permeabilized
in 0.2% Triton X-100 in PBS for 5 mins, and then blocked in fetal
bovine serum for 20 min. Primary antibodies were prepared in
10% fetal bovine serum supplemented with 0.2% saponin. After a
1 h incubation with primary antibody, cells were washed three
times with 0.2% Tween-20 and incubated for 1 h in secondary
antibody (conjugated to either Texas Red or FITC; Santa Cruz
Biotechnology, CA). Slides were mounted with Fluoromount-G
(Southern Biotech, AL). Images were collected with an AxioIma-
ger Z1 microscope (Carl Zeiss, Inc.) equipped with a color digital
camera (Axiocam MRc Rev.3; Carl Zeiss, Inc.) and Plan
Apochromat oil M27 lens (636, NA 1.4). Acquisition software
and image processing used the AxioVision software package (Carl
Zeiss, Inc.).
Mice
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocol was reviewed and approved by the Dana-Farber Cancer
Institute’s Animal Care and Use Committee (Protocol number 06-
029). All efforts were made to minimize suffering. Male Balb/c
mice were purchased from Taconic (NY, USA) and C57BL/6J
mice were purchased from The Jackson Laboratory (ME, USA).
For total body irradiation (TBI), mice were irradiated at the dose
rate of 110 cGy/min using a 137Cs source (GammacellH
40Exactor, Best Theratronics, Ottawa, Canada). DMOG (dis-
solved in saline) or saline was administered IP before and after
TBI. The mice were given normal water that had undergone
reverse osmosis and powdered food (Purina Pico Lab Chow) after
TBI. The animals were closely inspected after TBI for ill-health
and the moribund animals were sacrificed according to the
guidelines in our approved ACUC protocol. The Kaplan-Meier
survival curves were plotted for saline-treated and DMOG-treated
cohorts. The statistical analysis of the Kaplan-Meier survival
curves was performed with Graph Pad Prism Version 5 using
Mantel Log-rank test [59].
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